<- Go Home
Biora Therapeutics, Inc.
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
Market Cap
$6.3M
Volume
38.0K
Cash and Equivalents
$3.2M
EBITDA
-$60.4M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$892.0K
Profit Margin
100.00%
52 Week High
$19.90
52 Week Low
$1.43
Dividend
N/A
Price / Book Value
-0.06
Price / Earnings
-0.14
Price / Tangible Book Value
-0.06
Enterprise Value
$43.5M
Enterprise Value / EBITDA
-0.73
Operating Income
-$60.9M
Return on Equity
31.56%
Return on Assets
-154.63
Cash and Short Term Investments
$3.2M
Debt
$40.4M
Equity
-$106.6M
Revenue
$892.0K
Unlevered FCF
-$15.2M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium